Summary: Relay Therapeutics (RLAY) highlighted as top penny stock for growth potential in AI sector.
From Yahoo Finance: 2025-04-20 06:19:00
In a recent article, we highlighted the 11 most promising penny stocks based on analyst recommendations. Today, we focus on Relay Therapeutics, Inc. (NASDAQ: RLAY) and its position among other penny stocks.
On CNBC’s ‘Closing Bell,’ Solus’ Dan Greenhaus and Invesco’s Brian Levitt discussed market uncertainty and risk concerns. Greenhaus believes worst-case scenarios are already priced in and recent exemptions and delays show Trump’s responsiveness. Levitt cautions against relying solely on White House decisions and highlights potential downside risks if uncertainty persists.
Relay Therapeutics, Inc. (NASDAQ: RLAY) is a precision medicines company focused on drug discovery in oncology and genetic diseases. Its lead candidates include RLY-2608 for metastatic breast cancer. Barclays reiterated an Overweight rating with a $17 price target, citing positive Phase 1b data and plans for a Phase 3 trial in mid-2025.
Despite a decline in revenue in 2024, Relay ended the year with $781.3 million in cash. With ongoing clinical trials and emphasis on funding the Phase 3 trial, Relay remains optimistic. Ranked first on the list of promising penny stocks, RLAY demonstrates growth potential and AI stocks offer promising returns within a shorter timeframe.
For more insights on AI stocks and investment opportunities, check out our reports on the 20 Best AI Stocks to Buy Now and 30 Best Stocks to Invest in According to Billionaires. No disclosures. This article was originally published at Insider Monkey.
Read more: The Most Promising Penny Stock According to Analysts